Otsuka Holdings Co., Ltd.·Healthcare
Otsuka Holdings Co., Ltd. (OTSKY) M&A Call Prepared Remarks Transcript
Otsuka (OTCMKTS:OTSKY - Get Free Report) and Santen Pharmaceutical (OTCMKTS:SNPHY - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability. Profitability This table compares Otsuka and Santen Pharmaceutical's net
Mayne Pharma Group (OTCMKTS:MAYNF - Get Free Report) and Otsuka (OTCMKTS:OTSKY - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of recent
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with an increasing focus on products to treat or prevent gastrointestinal cancers, has added a new Phase 1 ready candidate to its portfolio, this time to target gastrointestinal stromal tumors, or GIST. Several drugs are available to treat GIST, but all ultimately fail when the tumor develops resistance.